4CPS-109 Descriptive analysis of patients co-infected with HIV and hepatitis C virus (HCV) treated with antivirals for HCV and its efficacy in a prison from 2002 to 2020. (23rd March 2022)

• Record Type: Journal Article
• Authors: Nogales-Garcia, M; Portu-Zapirain, J; Velasco-Garcia, R; Vargas, A; Beltran de Nanclares, L; Ollo, JJ; Fernandez, EM; Rosado, M; Santaolalla, A; Saez de Adana, E; Martinez, C
• Is Part Of: European journal of hospital pharmacy. Volume 29(2022)Supplement 1
• Page Start: A65
• Page End: A65
• Publication Date: 2022-03-23
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2022-eahp.137
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background and importance: The prevalence of patients with hepatitis C virus (HCV) viral load in national prisons was 3% in 2018, 2.5 times lower than the one obtained 10 years ago. In fact, since patients started to be treated with interferon-free-based treatments in 2015, a drastic decrease in HCV viral load prevalence was observed. Aim and objectives: To evaluate the response to treatment in inmates of a prison presenting HIV-HCV co-infection and that following treatment with HCV antiviral drugs. Material and methods: A descriptive observational study was conducted. The electronic clinical history and prescriptions of patients receiving HCV antivirals between 1 November 2002 and 31 December 2020 were reviewed. Moreover, the following data were collected: age, gender, HIV serology, discontinuation or not of the treatment and sustained viral response (SVR) at 12–24 weeks after treatment end. This response was defined as undetectable HCV-RNA 12–24 weeks after treatment compliance. The role of the pharmacist was adherence and adverse effects monitoring and to undertake an educational work. Results: During the study 251 patients were treated, of which 33.4% were co-infected with HIV-HCV. Their average age was 43 years and 86.9% were males. From 2002 to 2014, 33% of the 127 patients treated with interferon-based regimens were co-infected, and 50% of them obtained SVR, in contrast with mono-infected individuals, of whom 70.5% obtained SVR. Moreover, 28.5% co-infected patients did not respond to the treatment, 9.5% discontinued, 7.1% relapsed, 2.3% abandoned treatment because of intolerance and 2.3% were moved to another prison. However, between 2015 and 2020, from the 34.4% co-infected patients (from a total of 125) treated with interferon-free regimens (DDA), 95.2% obtained a SVR, meanwhile 92.5% of the mono-infected individuals obtained SVR. One of the co-infected patients relapsed and another obtained a response of breakthrough. Conclusion and relevance: The efficacy of antivirals in co-infected patients has increased due to the implementation of improved treatment guidelines, reaching more than 95% SVR with DDA, which approximates to the rates in the rest of the population. Treatment access for all patients and high treatment efficacy has led to 0% prevalence in this prison. References and/or acknowledgements: 1. Prevalencia de las infecciones VIH y VHC en Instituciones Penitenciarias 2018. Secretaria General de Instituciones Penitenciarias. Subdirección General de Coordinación de Sanidad Penitenciaria, 2018. Ministerio del Interior. Conflict of interest: No conflict of interest